| Interactions between Xenobiotics and DME (XEOTIC)
|
| Health or Environmental Toxicant(s) |
| Carcinogen |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Benzo(a)pyrene |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00898
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Carcinogen |
| DME Modulation |
Benzo(a)pyrene inhibits the expression of DME GGT5 |
[1] |
| Pharmaceutical Agent(s) |
| Approved/Marketed Drug |
Click to Show/Hide the Full List of Xenobiotics: 5 Xenobiotics
|
| Beclomethasone dipropionate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00278
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Beclomethasone dipropionate induces the drug-metabolizing activity of DME GGT5 |
[2] |
| Cyclosporine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00241
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cyclosporine up-regulates the expression of DME GGT5 |
[3] |
| Doxorubicin hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00292
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Doxorubicin hydrochloride inhibits the expression of DME GGT5 |
[4] |
| Fluticasone furoate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00297
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Fluticasone furoate induces the drug-metabolizing activity of DME GGT5 |
[2] |
| Progesterone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00094
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Progesterone up-regulates the expression of DME GGT5 |
[5] |
| Drug in Phase 3 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Triclosan |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00560
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Triclosan induces the drug-metabolizing activity of DME GGT5 |
[6] |
|
|
|
|
|
|